Atea Pharmaceuticals Inc Cash Flow Conversion Efficiency
Atea Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) has a cash flow conversion efficiency ratio of -0.182x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.08 Million) by net assets ($204.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Atea Pharmaceuticals Inc (2018–2025)
Cash flow conversion efficiency of Atea Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Atea Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Atea Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Atea Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Atea Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Atea Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atea Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Atea Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IVU Traffic Technologies AG
XETRA:IVU
|
0.126x |
|
Greenyard NV
BR:GREEN
|
0.189x |
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
N/A |
|
Karbon Capital Partners Corp. Class A Ordinary Shares
NASDAQ:KBON
|
-0.001x |
|
Hefei Changqing Machinery Co Ltd
SHG:603768
|
-0.004x |
|
Lanpec Technologies Ltd
SHG:601798
|
0.027x |
|
Zhenhai PetroChem Engineering
SHG:603637
|
0.031x |
|
Seoul Food
KO:004410
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atea Pharmaceuticals Inc from 2018 to 2025. Review how much free cash does Atea Pharmaceuticals Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.43 Million | $-132.03 Million | -0.479x | -55.26% |
| 2024-12-31 | $438.87 Million | $-135.50 Million | -0.309x | -100.73% |
| 2023-12-31 | $555.19 Million | $-85.39 Million | -0.154x | +18.56% |
| 2022-12-31 | $640.57 Million | $-120.98 Million | -0.189x | -54.14% |
| 2021-12-31 | $710.08 Million | $-87.00 Million | -0.123x | -122.62% |
| 2020-12-31 | $547.80 Million | $296.73 Million | 0.542x | +109.55% |
| 2019-12-31 | $-49.57 Million | $-12.81 Million | 0.258x | +18.20% |
| 2018-12-31 | $-36.16 Million | $-7.91 Million | 0.219x | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more